Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Clear all
Completed Phase 2 Interventional

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

NCT00310011
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
3
States / cities
Charlotte, North Carolina • Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

NCT03892642
View directory record Official record
Conditions
Bladder Cancer
Interventions
Avelumab, BCG
Drug · Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

A Cost Analysis of Interstim Therapy

NCT00200031
View directory record Official record
Conditions
Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)
Interventions
Interstim therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346
View directory record Official record
Conditions
Bladder Cancer
Interventions
Romidepsin, Durvalumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

NCT02891161
View directory record Official record
Conditions
Urothelial Cancer
Interventions
durvalumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Monika Joshi, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Iowa City, Iowa • Omaha, Nebraska • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Results available

Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury

NCT03083366
View directory record Official record
Conditions
Spinal Cord Injury, Acute, Neurogenic Bladder, Incontinence, Urinary Tract Infections
Interventions
PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Downey, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Withdrawn Not applicable Interventional

Neuromodulation Implantation Settings Variation for Overactive Bladder

NCT02112786
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting No phase listed Observational

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05981131
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting No phase listed Observational

Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial

NCT07726602
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Enrolling by invitation Not applicable Interventional

Peppermint Oil as a Treatment for Children With Bladder and Bowel Dysfunction

NCT05613153
View directory record Official record
Conditions
Bladder and Bowel Dysfunction
Interventions
Peppermint Oil
Dietary Supplement
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer

NCT03862105
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
Mobile Health app tool - Twistle
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound

NCT02923245
View directory record Official record
Conditions
Abdominal Pain, Pelvic Pain
Interventions
point-of-care ultrasound
Other
Lead sponsor
Lifespan
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

NCT00016237
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Lung Cancer
Interventions
tucotuzumab celmoleukin
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
MN-001 BID, MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Glendora, California • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

NCT00252941
View directory record Official record
Conditions
Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
Interventions
Memokath 028SW Urethral Stent
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

NCT00321477
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

NCT00003930
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
210
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)

NCT00704457
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

NCT00002919
View directory record Official record
Conditions
Bladder Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Viewing Surface Electrical Stimulation on Pelvic Floor With Ultrasound

NCT03528928
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Surface electrical stimulation
Device
Lead sponsor
Elidah, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Vitamin D Supplementation in Older Adults With Urinary Incontinence

NCT01971801
View directory record Official record
Conditions
Urinary Incontinence, Vitamin D Deficiency
Interventions
Vitamin D3 50,000 IU, Placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 25, 2026, 2:29 PM EDT